Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.39 |
| ▸ | CDK9 | P50750 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25449365 | 1.00 | RPS6KB1 (0.54) | RPS6KB1NTRK1CCNT1CDK9CDK2 | |
| SCHEMBL25449363 | 0.84 | SCN10A (0.40) | RPS6KB1CCNT1CDK9CDK2MAPK1 | |
| SCHEMBL30405926 | 0.81 | RPS6KB1 (0.55) | RPS6KB1NTRK1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL25449348 | 0.75 | CCR9 (0.43) | HPGDSMN1; SMN2FGFR1MAPK1 | |
| SCHEMBL25449364 | 0.73 | LCK (0.41) | — | |
| SCHEMBL20593671 | 0.71 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL20593675 | 0.71 | RPS6KB1 (1.00) | RPS6KB1 | |
| SCHEMBL12755258 | 0.70 | PIK3CA (0.54) | SMN1; SMN2FGFR1 | |
| Hydrochloric Acid SCHEMBL23289969 | 0.70 | RPS6KB1 (0.98) | RPS6KB1 | |
| SCHEMBL25449359 | 0.69 | ADORA1 (0.43) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | RPS6KB1 52/4885NTRK1 4414/4885CCNT1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.